Form 4 for AGIO AGIOS PHARMACEUTICALS, INC.
Accepted 2026-03-03 00:00:00 ET · period of report 2026-03-01 · accession 0001439222-26-000034 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2026-03-03 | 2026-03-02 | AGIO | Washburn Theodore James Jr. | Principal Accounting Off | S - Sale+OE | $28.96 | -2,223 | 6,140 | -27% | -$64.4K |
| DM | 2026-03-03 | 2026-03-02 | AGIO | Washburn Theodore James Jr. | Principal Accounting Off | M - OptEx | $0.00 | +7,495 | 3,293 | New | $0 |
| DM | 2026-03-03 | 2026-03-02 | AGIO | Washburn Theodore James Jr. | Principal Accounting Off | M - OptEx | $0.00 | -7,495 | 0 | -100% | $0 |
| D | 2026-03-03 | 2026-03-01 | AGIO | Washburn Theodore James Jr. | Principal Accounting Off | A - Grant | $0.00 | +8,452 | 8,452 | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common stock | 2026-03-02 | S | D | 698 | $28.96 | 2,595 | D | — | — | |
| 2 | Common | Common stock | 2026-03-02 | S | D | 727 | $28.96 | 4,243 | D | — | — | |
| 3 | Common | Common stock | 2026-03-02 | M | A | 2,695 | $0.00 | 6,938 | D | — | — | |
| 4 | Common | Common stock | 2026-03-02 | S | D | 798 | $28.96 | 6,140 | D | — | — | |
| 5 | Common | Common stock | 2026-03-02 | M | A | 2,450 | $0.00 | 4,970 | D | — | — | |
| 6 | Common | Common stock | 2026-03-02 | M | A | 2,350 | $0.00 | 3,293 | D | — | — | (F1) Includes 75 shares purchased through the Company's employee stock purchase plan. |
| 7 | Derivative | Restricted stock units | 2026-03-02 | M | D | 2,450 | $0.00 | 2,450 | D | — · — to — | 2,450 Common stock | (F5) Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. (F8) The restricted stock units were granted on March 1, 2024. Beginning on March 1, 2025, the shares underlying the restricted stock units will vest in three equal annual installments. |
| 8 | Derivative | Restricted stock units | 2026-03-02 | M | D | 2,695 | $0.00 | 5,390 | D | — · — to — | 2,695 Common stock | (F5) Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. (F9) The restricted stock units were granted on March 1, 2025. Beginning on March 1, 2026, the shares underlying the restricted stock units will vest in three equal annual installments. |
| 9 | Derivative | Restricted stock units | 2026-03-02 | M | D | 2,350 | $0.00 | 0 | D | — · — to — | 2,350 Common stock | (F5) Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. (F7) The restricted stock units were granted on March 1, 2023. Beginning on March 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments. |
| 10 | Derivative | Restricted stock units | 2026-03-01 | A | A | 8,452 | $0.00 | 8,452 | D | — · — to — | 8,452 Common stock | (F5) Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. (F6) The restricted stock units were granted on March 1, 2026. Beginning on March 1, 2027, the shares underlying the restricted stock units will vest in three equal annual installments. |